Duvelisib

ENSEM Expands its Leadership Team with the Appointment of Jeff Kutok, M.D., Ph.D. as Chief Scientific Officer

Retrieved on: 
Wednesday, January 3, 2024
Associate, Ipsen, Hospital, Science, Partnership, Duvelisib, Biotechnology, Drug development, Research, Pathology, Acquisition, BWH, Brigham and Women's Hospital, Therapy, EZH2, Verastem Oncology, Hematology, Stony Brook University, PI3K, Kinetic, Patient, Harvard Medical School, AbbVie, Management

WALTHAM, Mass., Jan. 3, 2024 /PRNewswire/ -- Ensem Therapeutics Inc., a biotechnology company focusing on high value and difficult-to-drug oncology targets, today announced the appointment of Dr. Jeff Kutok as Chief Scientific Officer, effectively immediately.

Key Points: 
  • WALTHAM, Mass., Jan. 3, 2024 /PRNewswire/ -- Ensem Therapeutics Inc., a biotechnology company focusing on high value and difficult-to-drug oncology targets, today announced the appointment of Dr. Jeff Kutok as Chief Scientific Officer, effectively immediately.
  • "Dr. Kutok is a seasoned executive with the right credentials to guide ENSEM's science into the future," stated Shengfang Jin, Ph.D., President & Chief Executive Officer of ENSEM.
  • Dr. Kutok previously served as Executive Vice President and Chief Scientific Officer at Infinity Pharmaceuticals, Inc. where he was responsible for the company's scientific strategy, preclinical development, and translational science.
  • "I am thrilled to join the ENSEM team at this exciting time," stated Dr. Jeff Kutok, Chief Scientific Officer at ENSEM.

Secura Bio, Inc. Receives Orphan Drug Designation in Europe for Duvelisib for the Treatment of Patients with Peripheral T-cell Lymphoma

Retrieved on: 
Monday, January 9, 2023
Duvelisib, EC, Food, Royal commission, PI3K, Patient, PTCL, Chronic lymphocytic leukemia, US Foods, Lymphocytosis, European Commission, Sustenance, Peripheral T-cell lymphoma, Marketing, Pharmaceutical industry, EU

Duvelisib was previously granted orphan drug designation by the United States Food and Drug Administration.

Key Points: 
  • Duvelisib was previously granted orphan drug designation by the United States Food and Drug Administration.
  • Orphan Drug Designation in the EU is granted by the EC based on a positive opinion issued by the European Medicines Agency Committee for Orphan Medicinal Products.
  • "This Orphan Drug Designation recognizes the significant unmet need in patients with PTCL, especially those with relapsed/refractory disease.
  • "Secura Bio is dedicated to developing duvelisib for the treatment of patients with difficult-to-treat cancers, which includes relapsed/refractory PTCL.

Nucleai Expands Scientific Advisory Board with Oncology Industry Luminary Dr. Julian Adams

Retrieved on: 
Tuesday, November 8, 2022
Research, Technology, Other Technology, Nanotechnology, Software, Biotechnology, Pharmaceutical, Health, Data Management, Science, Takeda Oncology, Industry, MIT, Boehringer Ingelheim, HIV, Precision medicine, Cancer, Machine learning, Multiple myeloma, Bortezomib, Nevirapine, Drug discovery, Degenerative disease, Laboratory, SAB, Massachusetts Institute of Technology, McGill University, Science, Pathology, Duvelisib, Decision-making, PI3K, Multimedia, Knowledge, CEO, Fine chemical, Medical device, Pharmaceutical industry

Nucleai, an AI-powered spatial biology leader, announced that Dr. Julian Adams has joined its scientific advisory board.

Key Points: 
  • Nucleai, an AI-powered spatial biology leader, announced that Dr. Julian Adams has joined its scientific advisory board.
  • His distinguished career in the pharmaceutical and biopharmaceutical industry includes senior leadership roles at Millennium Pharmaceuticals (now part of Takeda Oncology), Infinity Pharmaceuticals, Boehringer Ingelheim, and Gamida Cell.
  • View the full release here: https://www.businesswire.com/news/home/20221108005776/en/
    Were excited to welcome Dr. Julian Adams to Nucleais scientific advisory board.
  • Dr. Adams holds more than 40 patents and has won industry and academic awards.

Nuvalent Announces Leadership Promotions

Retrieved on: 
Wednesday, July 20, 2022
Chemistry, Duvelisib, View, Pharmaceutical Development and Technology, Biogen, Degenerative disease, U.S. Securities and Exchange Commission, Twitter, Hematology, Alpha-galactosidase, IND World's Fair Line, Research, HER2, Risk, Private Securities Litigation Reform Act, Government, Merck Serono, Brain, COVID-19, Multimedia, Cancer, Leadership, Quality assurance, Agios, Merck, Drug development, NSCLC, Company, Senior, Security (finance), Texas A&M University, LinkedIn, Patient, Nasdaq, ALK, Therapy, Neurology, Sanofi, Annual report, LLC, Columbia University, Harvard University, Management, Pharmaceutical industry, Architecture, Genzyme, Ivosidenib, Avelumab, Plerixafor, Infinity

CAMBRIDGE, Mass., July 20, 2022 /PRNewswire/ -- Nuvalent, Inc. (Nasdaq: NUVL), a clinical-stage biopharmaceutical company focused on creating precisely targeted therapies for clinically proven kinase targets in cancer, today announced two leadership team promotions. Darlene Noci, A.L.M. has been promoted to Chief Development Officer and will continue to oversee all global Product Development and Regulatory Affairs activities. Benjamin Lane, Ph.D. has been promoted to Senior Vice President, Technical Operations and will continue to oversee all Pharmaceutical Development and Quality Assurance activities.

Key Points: 
  • Benjamin Lane, Ph.D. promoted to Senior Vice President, Technical Operations
    CAMBRIDGE, Mass., July 20, 2022 /PRNewswire/ -- Nuvalent, Inc. (Nasdaq: NUVL), a clinical-stage biopharmaceutical company focused on creatingpreciselytargeted therapies for clinically proven kinase targets in cancer, today announced two leadership team promotions.
  • Prior to joining Nuvalent, Ms. Noci held various regulatory, quality assurance and global development team leadership positions with increasing responsibility at X4 Pharmaceuticals, EMD Serono, Infinity, Sanofi, and Genzyme.
  • "These promotions reflect the significant contributions made by Darlene and Ben in establishing Nuvalent as a clinical-stage company with strong expertise in the development of novel oncology therapies," said James Porter, Ph.D., Chief Executive Officer at Nuvalent.
  • We routinely post information that may be important to investors on our website at www.nuvalent.com .Follow us on Twitter ( @nuvalent ) and LinkedIn .

Verastem Oncology Reports First Quarter 2022 Financial Results and Highlights Recent Company Progress

Retrieved on: 
Monday, May 9, 2022
Biotechnology, Other Health, Health, Pharmaceutical, Oncology, Verastem Oncology, GAAP, American Association for Cancer Research, BRAF, CRAF, ARAF, FAK, SECURA Insurance, General Administration of Sport of China, Medicare Part D, SEC, Amgen, Shijiazhuang Pharma Group, Mission statement, FRAME, Company, Patient, American Association, Breakthrough therapy, Sanofi, National Medical Products Administration, Large-cell lung carcinoma, U.S. Securities and Exchange Commission, Investment, CSPC, Oxford, Neoplasm, Research, Security (finance), Government, Association, RAS, NSCLC, RAMP, Sale, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Oncology, MEK, AACR, RAF, Table, Food, Â, Duvelisib, Cancer, Patent, Research and development, Adult, Income, Mirati, Pharmaceutical industry, Medical imaging, Medicine, Video game, Bank, Part

Verastem Oncology (Nasdaq: VSTM), a biopharmaceutical company committed to advancing new medicines for patients with cancer, today reported financial results for the three months ended March 31, 2022 and highlighted recent progress.

Key Points: 
  • Verastem Oncology (Nasdaq: VSTM), a biopharmaceutical company committed to advancing new medicines for patients with cancer, today reported financial results for the three months ended March 31, 2022 and highlighted recent progress.
  • Verastem plans to report topline results from Part A during the second quarter of 2022, following discussions with regulatory authorities.
  • The Company expects to report topline results from Part A and initiate Part B during the second half of 2022, following discussions with regulatory authorities.
  • Verastem Oncology ended the first quarter 2022 with cash, cash equivalents and investments of $106.3 million.

Verastem Oncology Provides Financial Update to Support Development of VS-6766 and Defactinib in RAS Pathway-Driven Tumors

Retrieved on: 
Monday, March 28, 2022
Biotechnology, Pharmaceutical, Health, Oncology, Company, Mirati, RAMP, Sale, Patent, BRAF, Government, CRAF, Oxford, KRAS, SEC, Cancer, Verastem Oncology, MEK, Food, U.S. Securities and Exchange Commission, NSCLC, Security (finance), FAK, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Duvelisib, Breakthrough therapy, RAS, Solution, RAF, Finance, Oncology, ARAF, Patient, Amgen, Pharmaceutical industry, Medical imaging, VS-6766, VERASTEM ONCOLOGY, OXFORD FINANCE LLC

Under the terms of the loan agreement with Oxford Finance LLC, Verastem drew an initial $25 million term loan at closing.

Key Points: 
  • Under the terms of the loan agreement with Oxford Finance LLC, Verastem drew an initial $25 million term loan at closing.
  • The Company had cash, cash equivalents, and investment balance of $100.3 million as of December 31, 2021.
  • Verastem Oncology (Nasdaq: VSTM) is a development-stage biopharmaceutical company committed to the development and commercialization of new medicines to improve the lives of patients diagnosed with cancer.
  • Verastem Oncology Receives Breakthrough Therapy Designation for VS-6766 with Defactinib in Recurrent Low-Grade Serous Ovarian Cancer.

Avenge Bio Appoints Claudio Dansky Ullmann, M.D., as Chief Medical Officer

Retrieved on: 
Monday, March 28, 2022
Cancer, Lung, National Cancer Institute, Immunotherapy, Multimedia, Rice University, CAR, Biotechnology, Research, Universidad, National Institutes of Health Clinical Center, Neoplasm, National Institute, Takeda, SVP, Science Advances, Ovarian cancer, View, Industry, Technology, CLL, Drug resistance, The Company, Drug, Financial toxicity, NCI, National, Patient, Pharmaceutical industry, IND, Science, Duvelisib

NATICK, Mass., March 28, 2022 /PRNewswire/ -- Avenge Bio, Inc. ("Avenge" or the "Company"), a biotechnology company developing the LOCOcyte immunotherapy platform for the precision administration of potent immune effector molecules to treat solid tumors, today announced the appointment of medical oncologist, Claudio Dansky Ullmann, M.D., as Chief Medical Officer.

Key Points: 
  • NATICK, Mass., March 28, 2022 /PRNewswire/ -- Avenge Bio, Inc. ("Avenge" or the "Company"), a biotechnology company developing the LOCOcyte immunotherapy platform for the precision administration of potent immune effector molecules to treat solid tumors, today announced the appointment of medical oncologist, Claudio Dansky Ullmann, M.D., as Chief Medical Officer.
  • "We are very pleased to have Dr. Dansky Ullmann join Avenge as our Chief Medical Officer at this key stage of our clinical pipeline development," said Michael Heffernan, Chief Executive Officer of Avenge.
  • Most recently, he was the Chief Medical Officer of MaxCyte CARMA Cell Therapies, where he oversaw clinical development, operations, regulatory and translational medicine functions.
  • Avenge Bio, Inc. ("Avenge") is an oncology-focused biotechnology company developing transformative cell-based immunotherapeutic products for the treatment of intractable solid tumors by incorporating its LOCOcyteplatform.

Transgene Appoints Steven Bloom as Chief Business Officer

Retrieved on: 
Thursday, February 10, 2022
Biotechnology, Infectious Diseases, Other Health, Health, Pharmaceutical, Precision medicine, Duvelisib, Eli Lilly, Company, Cancer, Vaccination, Marketing, NEC, Sale, KOL, Artificial intelligence, Program, Antibody-drug conjugate, AMF, Euronext Paris, Rest, TNG, Verastem Oncology, Immunotherapy, AstraZeneca, Goal, Vaccine, BS, Corporate Affairs, Potyvirus, Risk, Forward-looking statement, Management, Pharmacy, Transgene, Euronext, Northeastern University

Transgene (Euronext Paris: TNG) (Paris:TNG), a biotech company that designs and develops virus-based immunotherapeutics against cancer, announced today that it has appointed Steven Bloom as Vice President, Chief Business Officer with immediate effect.

Key Points: 
  • Transgene (Euronext Paris: TNG) (Paris:TNG), a biotech company that designs and develops virus-based immunotherapeutics against cancer, announced today that it has appointed Steven Bloom as Vice President, Chief Business Officer with immediate effect.
  • We welcome Steven to the Transgene management team and are delighted to appoint a professional of his caliber to lead our global business development activities," said Hedi Ben Brahim CEO of Transgene.
  • Im looking forward to working with the rest of the team and manage potential business deals and partnerships to take Transgenes pipeline to the next level, added Steven Bloom.
  • Prior to joining Transgene, Mr. Bloom was Senior Vice President at Boston Pharmaceuticals and before that he was Chief Business Officer at Vavotar Life Sciences (formerly known as NantiBodyFc).

COPIKTRA® (duvelisib) Receives European Union Marketing Authorization for the Treatment of Relapsed or Refractory CLL and Refractory FL

Retrieved on: 
Wednesday, June 9, 2021
Antineoplastic drugs, Clinical medicine, Medicine, Medical specialties, Oncology, Orphan drugs, Hematology, Duvelisib, Tumors of the hematopoietic and lymphoid tissues, Bone marrow failure, Monoclonal B-cell lymphocytosis, Chronic lymphocytic leukemia

CLL and FL are slow-growing incurable blood cancers that can lead to life-threatening complications such as anemia, serious infections, and bone marrow failure requiring treatment.

Key Points: 
  • CLL and FL are slow-growing incurable blood cancers that can lead to life-threatening complications such as anemia, serious infections, and bone marrow failure requiring treatment.
  • "This market authorization is an important step in helping patients suffering from relapsed or refractory CLL and FL who currently have limited options and poor outcomes.
  • "With the market authorization of COPIKTRA in the European Union, Secura Bio will have two meaningful oncology drugs with novel modes of action.
  • "COPIKTRA provides European physicians and patients with another valuable and beneficial option to combat these debilitating illnesses.

COPIKTRA® (duvelisib) Receives European Union Marketing Authorization for the Treatment of Relapsed or Refractory CLL and Refractory FL

Retrieved on: 
Wednesday, June 9, 2021
Antineoplastic drugs, Clinical medicine, Medicine, Medical specialties, Oncology, Orphan drugs, Hematology, Duvelisib, Tumors of the hematopoietic and lymphoid tissues, Bone marrow failure, Monoclonal B-cell lymphocytosis, Chronic lymphocytic leukemia

CLL and FL are slow-growing incurable blood cancers that can lead to life-threatening complications such as anemia, serious infections, and bone marrow failure requiring treatment.

Key Points: 
  • CLL and FL are slow-growing incurable blood cancers that can lead to life-threatening complications such as anemia, serious infections, and bone marrow failure requiring treatment.
  • "This market authorization is an important step in helping patients suffering from relapsed or refractory CLL and FL who currently have limited options and poor outcomes.
  • "With the market authorization of COPIKTRA in the European Union, Secura Bio will have two meaningful oncology drugs with novel modes of action.
  • "COPIKTRA provides European physicians and patients with another valuable and beneficial option to combat these debilitating illnesses.